Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SDX-105 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SDX-105 | DRUG | - |
Inclusion Criteria: * Documented indolent or transformed B-Cell NHL indolent NHL: follicular B-Cell lymphoma, diffuse small lymphocytic lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma * Documented refractory disease to rituximab therapy, given as a single agent or in combination (defin...
SDX-105 is used for the treatment of Non-Hodgkin's Lymphoma. It is being investigated as a therapy for patients with rituximab refractory Non-Hodgkin's Lymphoma, meaning the cancer has not responded to prior treatment with rituximab.
SDX-105 is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting clinical research on this small molecule drug for the oncology indication of Non-Hodgkin's Lymphoma.
SDX-105 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety and activity in patients.
SDX-105 has one completed clinical trial, identified as NCT00069758. This Phase 2 study, titled "Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma," enrolled 72 participants across the United States and Canada.
Yes, SDX-105 is also known as bendamustine. The clinical trial NCT00069758 refers to SDX-105 as bendamustine in its title, confirming that these names refer to the same drug being studied for Non-Hodgkin's Lymphoma.